Hepatocentric approach to achieving compensation of diabetes mellitus in people with non-alcoholic steatohepatitis

Hepatocentric approach to achieving compensation of diabetes mellitus in people with non-alcoholic steatohepatitis

Background. Non-alcoholic steatohepatitis (NASH) in individuals with type 2 diabetes mellitus (T2DM) is considered a comorbid condition with an unfavorable prognosis and a significant economic burden on the global healthcare system. Despite patient-centered treatment goals and the coordinated effor...

Full description

Saved in:

Bibliographic Details
Main Authors:	N.M. Protas, I.O. Kostitska, M.V. Bielinskyi
Format:	Article
Language:	English
Published:	Zaslavsky O.Yu. 2024-09-01
Series:	Mìžnarodnij Endokrinologìčnij Žurnal
Subjects:	type 2 diabetes mellitus non-alcoholic steatohepatitis sodium-glucose cotransporter 2 inhibitors dapagliflozin
Online Access:	https://iej.zaslavsky.com.ua/index.php/journal/article/view/1423
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

New opportunities for the correction of type 2 diabetes mellitus in patients with liver diseases
by: L. Yu. Morgunov, et al.
Published: (2022-01-01)

Dapagliflozin effectiveness in improvement of clinical outcomes in diabetic patients (extention of CARDIA-MOS study, Moscow)
by: M. B. Antsiferov, et al.
Published: (2025-02-01)

Randomized Trial of SGLT2 Inhibitor Identifies Target Proteins in Diabetic Kidney Disease
by: Tarunveer S. Ahluwalia, et al.
Published: (2024-02-01)

Application of ursodeoxycholic acid at non-alcoholic and alcohol-induced steatohepatitis
by: Ye. A. Fedos’ina, et al.
Published: (2010-06-01)

SGLT2 inhibitor administration to two patients with diabetes mellitus with ascites due to cirrhosis
by: Koji Nagayama, et al.
Published: (2025-07-01)

The impacts of SGLT2 inhibitors on the mortality of patients with tuberculosis
by: Chung-Shu Lee, et al.
Published: (2025-05-01)

Comprehensive treatment of patients with type 2 diabetes, complicated by diabetic kidney disease, with concomitant non-alcoholic steatohepatitis
by: Z.Ya. Kotsiubiichuk, et al.
Published: (2025-04-01)

Sodium-glucose cotransporter 2 inhibitors as potential anticancer agents
by: E. R. Radkevich, et al.
Published: (2025-05-01)

Real‐world data on Empagliflozin and Dapagliflozin use in patients with HEART failure: The RED–HEART study
by: Umut Kocabas, et al.
Published: (2025-02-01)

Effect of sodium-glucose cotransporter-2 inhibitor on metabolic syndrome in people with prediabetes and obesity: A systematic review and meta-analysis
by: Sadia Bari, et al.
Published: (2025-06-01)

Association of sodium-glucose cotransporter-2 inhibitor use and mortality in patients with endometrial cancer: a retrospective cohort study
by: Min Wang, et al.
Published: (2025-07-01)

Drug Therapy for Non-Alcoholic Steatohepatitis-Induced Liver Fibrosis
by: D. V. Garbuzenko
Published: (2022-01-01)

Correction of the clinical course of non-alcoholic steatohepatitis and diabetic kidney disease in patients with type 2 diabetes
by: Z.Ya. Kotsiubiichuk, et al.
Published: (2024-10-01)

Changes in direct markers of liver fibrosis in patients with steatohepatitis non-alcoholic and alcoholic origin on the background of obesity and pathology of the biliary tract
by: A. Yu. Filippova
Published: (2017-04-01)

Deposition features of heterovalent iron (Fe2 + and Fe3 +) in the liver in alcoholic and nonalcoholic steatohepatitis
by: V. A. Tumanskiy, et al.
Published: (2015-12-01)

Open-Label, Randomized, Controlled, Crossover Trial on the Effect of Dapagliflozin in Patients With ADPKD Receiving Tolvaptan
by: Kiyotaka Uchiyama, et al.
Published: (2025-04-01)

Perioperative euglycemic DKA: The YIN and YANG of sodium-glucose cotransporter 2 inhibitors
by: Shilpushp Bhosale, et al.
Published: (2025-01-01)

Efficacy and safety of sodium-glucose cotransporter-2 inhibitors in type 2 diabetes mellitus with inadequate glycemic control on insulin: a network meta-analysis
by: M. V. Shestakova, et al.
Published: (2025-01-01)

Factors influencing early renal function changes after SGLT2 inhibitors use and its long-term prognosis: a real-world retrospective study
by: Bing Xie, et al.
Published: (2025-12-01)

Early Initiation of Sodium–Glucose Cotransporter 2 Inhibitors in Acute Heart Failure: A Systematic Review and Meta‐Analysis
by: Miloud Cherbi, et al.
Published: (2025-04-01)

Differential glycemic effects of DWP16001 in diabetic dogs according to baseline glycemic status: a multicenter randomized controlled trial
by: Ju-Hyun An, et al.
Published: (2025-08-01)

Quantitative longitudinal investigation of non-alcoholic steatohepatitis in mice by photoacoustic microscopy
by: Jianshuang Wei, et al.
Published: (2025-08-01)

Safety and effectiveness of ipragliflozin in Japanese patients with type 2 diabetes mellitus and impaired renal function: subgroup analysis of a 3-year post-marketing surveillance study (STELLA-LONG TERM)
by: K. Tobe, et al.
Published: (2021-07-01)

A case of pyelonephritis and bacteremia caused by Candida glabrata in a patient on sodium glucose cotransporter 2 inhibitor, successfully treated with micafungin
by: Shoko Sahara, et al.
Published: (2025-08-01)

Progress in studies on renal effects and molecular mechanism of SGLT-2 inhibitors
by: XING Bei, et al.
Published: (2020-01-01)

Early hemodynamic impact of SGLT2 inhibitors in overweight cardiometabolic heart failure: beyond fluid offloading to vascular adaptation– a preliminary report
by: Nadia Salerno, et al.
Published: (2025-03-01)

Antifibrotic effects of sodium-glucose cotransporter 2 inhibitors in patients with heart failure
by: Yu. S. Ignatova, et al.
Published: (2024-02-01)

Sodium-glucose cotransporter type 2 inhibitors: successful running after two hares
by: N. B. Perepech, et al.
Published: (2021-07-01)

Induction of proximal tubular proliferation and lengthening in response to sodium glucose linked cotransporter‐2 inhibition in experimental rats
by: Ellen Wu, et al.
Published: (2025-07-01)

Ipragliflozin improves the hepatic outcomes of patients with diabetes with NAFLD
by: Hirokazu Takahashi, et al.
Published: (2025-05-01)

A case of perioperative euglycemic ketoacidosis in a patient without diabetes: are current guidelines enough?
by: Shushmita Hoque, et al.
Published: (2025-07-01)

Steatohepatitis in Children with Obesity
by: Alexander A. Zvyagin, et al.
Published: (2021-08-01)

Is It Time for Polypill in Heart Failure Therapy? Current Preference among Indian Cardiologists: A Cross-sectional Survey
by: Kamal Sharma, et al.
Published: (2025-01-01)

SGLT2 inhibitors in lupus nephritis: a multicentric study in Latin America
by: José L. Daza, et al.
Published: (2025-04-01)

Genomic insights about the effect of sodium-glucose cotransporter 2 inhibitors: a systematic review
by: Pavitraa Saravana Kumar, et al.
Published: (2025-05-01)

Impact of dapagliflozin on metabolic phenotype, hormone levels, and fertility in female mice after prolonged high-fat diet
by: Xiaolin Chen, et al.
Published: (2025-01-01)

SGLT2 Inhibitors: From Molecular Mechanisms to Clinical Outcomes in Cardiology and Diabetology
by: Marlena Stielow, et al.
Published: (2025-07-01)

Identification of biomarkers between coronary artery disease and non-alcoholic steatohepatitis: a combination of bioinformatics and machine learning
by: Yihong Lin, et al.
Published: (2025-07-01)

1,25-dihydroxyvitamin D3 improves non-alcoholic steatohepatitis phenotype in a diet-induced rat model
by: Mei Liu, et al.
Published: (2025-03-01)

Immune and Inflammatory Pathways in Non-Alcoholic Steatohepatitis (NASH). An update
by: Sorina Cezara Coste, et al.
Published: (2019-05-01)